Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Lujia ChenYing Wang Chunhui Cai Ying DingRim S KimCorey LipchikPatrick G GavinGreg YothersCarmen J AllegraNicholas J PetrelliJennifer Marie SugaJudith O Hopkins Naoyuki G SaitoTerry EvansSrinivas JujjavarapuNorman Wolmark Peter C Lucas Soonmyung Paik Min SunKatherine L Pogue-GeileXinghua Lu

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

The COLOXIS model is predictive of oxaliplatin benefits in the CC adjuvant setting. The results provide evidence supporting a change in CC adjuvant therapy: reserve oxaliplatin only for COLOXIS+ patients, but further investigation is warranted.

Keyphrases

machine learning
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
early stage
peritoneal dialysis
patient reported outcomes
patient reported